CEREZYME Drug Profile

Summary for Tradename: CEREZYME

High Confidence Patents:	2
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for CEREZYME
Recent Clinical Trials:	See clinical trials for CEREZYME

See drug prices for CEREZYME

Recent Clinical Trials for CEREZYME

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Genzyme, a Sanofi Company	Phase 3
ISU Abxis Co., Ltd.	Phase 1
Sanofi	N/A

See all CEREZYME clinical trials

Pharmacology for CEREZYME

Established Pharmacologic Class	Hydrolytic Lysosomal Glucocerebroside-specific Enzyme
Chemical Structure	Glucosylceramidase

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for CEREZYME Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for CEREZYME Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2011-08-21	DrugPatentWatch analysis and company disclosures
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2013-06-21	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for CEREZYME Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2036-12-20	Patent claims search
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2036-07-29	Patent claims search
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2033-11-19	Patent claims search
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2037-12-26	Patent claims search
Genzyme Corporation	CEREZYME	imiglucerase	For Injection	020367		2038-12-19	Patent claims search

International Patents for CEREZYME

Country	Patent Number	Estimated Expiration
Germany	68926569
Japan	H03503721
European Patent Office	0401362
Canada	2006709
Japan	2893481

Market Dynamics and Financial Trajectory for CEREZYME (Imiglucerase)

Last updated: February 19, 2026

What is the current market position of CEREZYME?

CEREZYME (imiglucerase) is a recombinant enzyme therapy developed by Sanofi that treats Gaucher disease, a rare lysosomal storage disorder characterized by glucocerebroside accumulation. It received FDA approval in 1994 and has since established a significant presence in the rare disease market.

How has the demand for CEREZYME evolved?

Demand is driven by:

• Prevalence of Gaucher disease: Approximately 1 in 40,000 to 60,000 live births worldwide, with higher incidence in Ashkenazi Jewish populations.
• Number of approved patients: Estimated at 2,000 globally, with the majority in North America and Europe.
• Treatment adoption rates: Consistent due to the absence of curative therapies; enzyme replacement therapy (ERT) remains standard.
• Pricing models: CEREZYME’s annual treatment cost ranges from $200,000 to $400,000 per patient, impacting revenue stability.

What are the key market dynamics influencing CEREZYME?

Competitive landscape

CEREZYME faces competition from:

• Vpriv (velaglucerase alfa): Developed by Takeda, approved in 2014.
• Zavesca (miglustat): Orally administered, approved for certain Gaucher types.
• Substrate reduction therapies and gene therapy: Emerging treatments that could alter the market landscape.

Pricing and reimbursement

Pricing pressure stems from:

• Payer negotiations aiming to reduce costs.
• Variable reimbursement policies across countries.
• The high cost of therapy influencing healthcare budgets.

Regulatory and policy environments

Stringent regulatory standards influence:

• Market entry for biosimilars.
• Re-evaluation of treatment efficacy and safety.
• Incentives and policies for orphan drugs.

Manufacturing and supply chain

Production complexity:

• Requires specialized biomanufacturing facilities.
• Supply chain disruptions could impact availability.

How is CEREZYME's financial trajectory projected?

Revenue trends

• Historical revenue: Sanofi reported CEREZYME revenue of €701 million (~$766 million) in 2020.
• Growth factors: Increase in treated patients, expanding global access, and price adjustments.
• Market saturation: Limited growth potential due to the small patient population.

Revenue forecasts

Based on market trends:

Year	Estimated Revenue (USD millions)	Key Assumptions
2022	750	Steady demand, no major market disruptions
2023	770	Slight increase due to expanding access
2024	780	Market growth slows as treatment options diversify
2025	785	Market reaches saturation; growth stabilizes

Cost considerations

• Manufacturing costs: Remain high due to complex bioprocessing.
• R&D investments: Minimal for existing product, some allocated toward biosimilar efforts.
• Market access costs: Rising due to pricing pressures and reimbursement negotiations.

Profitability outlook

Given high per-patient costs and limited patient base, margins rely heavily on maintaining treatment volume and managing manufacturing expenses. Growth hinges on expanding indications and geographic reach.

What are the future market and financial risks?

• Emerging therapies: Gene editing and substrate reduction therapies could reduce CEREZYME's market share.
• Pricing and reimbursement: Increasing pressures could limit revenue growth.
• Market entry of biosimilars: Biosimilar versions of imiglucerase could undercut pricing.
• Regulatory hurdles: New policies for orphan drugs could restrict market access.

Key Takeaways

• CEREZYME remains the market leader in Gaucher disease enzyme therapy, with stable but limited growth prospects.
• Revenue consistently exceeds $750 million annually, driven by access expansion.
• Competition and biosimilar threats pose risks to long-term profitability.
• Market dynamics are heavily influenced by treatment costs, patient prevalence, and regulatory policies.

FAQs

1. What is the main driver of CEREZYME's revenue?
Treating the small but stable population of Gaucher disease patients using enzyme replacement therapy.

2. How does CEREZYME compare to its competitors?
It maintains market dominance over newer therapies like Vpriv, but faces declining margins from pricing pressures and biosimilar entries.

3. What emerging therapies could impact CEREZYME?
Gene therapies and substrate reduction treatments are in development and could reduce the need for enzyme replacement.

4. How does reimbursement affect CEREZYME sales?
Economic negotiations and policy changes influence access and reimbursement rates, impacting revenue.

5. What is the long-term outlook for CEREZYME's financials?
Limited growth driven by market saturation and competition; profitability depends on managing costs and expanding indications.

---

References

[1] Sanofi. (2021). CEREZYME Product Details. Retrieved from https://www.sanofi.com/en/products/cerezyme
[2] National Institutes of Health. (2022). Gaucher Disease Fact Sheet. Retrieved from https://www.ninds.nih.gov/health-information/disorders/gaucher-disease
[3] Evaluate Pharma. (2022). Orphan Drug Market Analysis.
[4] FDA. (2014). Vpriv (velaglucerase alfa) Approval Announcement.
[5] MarketWatch. (2022). Gaucher disease therapeutics market analysis.